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MAJOR ARTICLE
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Background. It is unclear if the risk of liver disease associated with different levels of alcohol consumption is
higher for patients infected with human immunodeﬁciency virus (HIV) or chronic hepatitis C virus (HCV). We
evaluated associations between alcohol use categories and advanced hepatic ﬁbrosis, by HIV and chronic HCV status.
Methods. We performed a cross-sectional study among participants in the Veterans Aging Cohort Study who
reported alcohol consumption at enrollment (701 HIV/HCV-coinfected; 1410 HIV-monoinfected; 296 HCVmonoinfected; 1158 HIV/HCV-uninfected). Alcohol use category was determined by the Alcohol Use Disorders
Identiﬁcation Test–Consumption (AUDIT-C) questionnaire and alcohol-related diagnoses and was classiﬁed as nonhazardous drinking, hazardous/binge drinking, or alcohol-related diagnosis. Advanced hepatic ﬁbrosis was deﬁned by
FIB-4 index >3.25.
Results. Within each HIV/HCV group, the prevalence of advanced hepatic ﬁbrosis increased as alcohol use category increased. For each alcohol use category, advanced hepatic ﬁbrosis was more common among HIV-infected than
uninfected (nonhazardous: 6.7% vs 1.4%; hazardous/binge: 9.5% vs 3.0%; alcohol-related diagnosis: 19.0% vs 8.6%;
P < .01) and chronic HCV-infected than uninfected (nonhazardous: 13.6% vs 2.5%; hazardous/binge: 18.2% vs
3.1%; alcohol-related diagnosis: 22.1% vs 6.5%; P < .01) participants. Strong associations with advanced hepatic ﬁbrosis
(adjusted odds ratio [95% conﬁdence interval]) were observed among HIV/HCV-coinfected patients with nonhazardous drinking (14.2 [5.91–34.0]), hazardous/binge drinking (18.9 [7.98–44.8]), and alcohol-related diagnoses (25.2
[10.6–59.7]) compared with uninfected nonhazardous drinkers.
Conclusions. Advanced hepatic ﬁbrosis was present at low levels of alcohol consumption, increased with higher
alcohol use categories, and was more prevalent among HIV-infected and chronic HCV-infected patients than
uninfected individuals. All alcohol use categories were strongly associated with advanced hepatic ﬁbrosis in
HIV/HCV-coinfected patients.
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Alcohol consumption is prevalent among human immunodeﬁciency virus (HIV)–infected [1–3] and chronic hepatitis C virus
(HCV)–infected [4] patients and is an important contributor to
progression of liver ﬁbrosis in these groups [5, 6]. Excessive alcohol intake is associated with a range of hepatic manifestations, including hepatic inﬂammation, ﬁbrosis, and steatosis,
which can lead to cirrhosis and hepatic decompensation [7].
Despite the acknowledged impact of alcohol on the liver, few
studies have evaluated the effects of different patterns of alcohol
consumption on liver disease, particularly among persons with
HIV or chronic HCV. Furthermore, it is unclear if the risk of
liver disease associated with each level of alcohol use is higher
for those with HIV or chronic HCV. Given the prevalence of
alcohol consumption in these groups [1, 2, 4], it is important
to determine if certain patterns of alcohol use—such as nonhazardous and binge drinking, which are traditionally not thought
to contribute to hepatic ﬁbrosis—are harmful to the liver, and
more so for those infected with HIV or chronic HCV.
Although biopsy has been the gold standard for staging liver
disease, it is not feasible to perform liver biopsies in large cohort
studies because of the costs and risks to patients [8]. Noninvasive markers of hepatic ﬁbrosis have been valuable for evaluating liver disease in population-based studies [9], particularly in
HIV-infected cohorts [10–12]. The FIB-4 index (based on liver
aminotransferases, platelet count, and age) is a noninvasive, validated measure of advanced hepatic ﬁbrosis in patients with
chronic liver disease, including alcoholic liver disease [13], viral
hepatitis [14–17], and HIV/viral hepatitis coinfection [18], and
can predict liver-related mortality among HCV-monoinfected
[19–21] and HIV/HCV–coinfected patients [20, 21].
Our objective was to evaluate the association between alcohol
use categories and advanced hepatic ﬁbrosis, determined by FIB4 index, by HIV and chronic HCV status among participants in
the Veterans Aging Cohort Study (VACS), an ongoing cohort established to examine the effects of alcohol and comorbidities on
health outcomes [22]. We hypothesized that for each category of
alcohol use, the prevalence of advanced ﬁbrosis would be greater
in persons infected with HIV or chronic HCV compared with uninfected persons. We also examined associations between alcohol
use categories and advanced hepatic ﬁbrosis among HIV/HCVcoinfected, HIV-monoinfected, HCV-monoinfected, and HIV/
HCV-uninfected patients, to gain insights into the effects of
HIV, chronic HCV, and alcohol use on signiﬁcant liver ﬁbrosis.
PATIENTS AND METHODS
Study Design and Data Source

We conducted a cross-sectional study among participants
receiving medical care at 1 of 8 VACS sites (Veterans Health
Administration [VA] facilities in Atlanta, Georgia; Baltimore,
Maryland; Bronx, New York; Houston, Texas; Los Angeles,
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California; Manhattan, New York; Pittsburgh, Pennsylvania;
Washington, D.C.) [22]. VACS follows HIV-infected patients
group matched in a 1:1 ratio to uninfected patients by age, sex,
race/ethnicity, and clinical site. At enrollment, participants complete a standardized questionnaire that collects demographic information, alcohol use (determined using the Alcohol Use
Disorders Identiﬁcation Test-Consumption [AUDIT-C] questionnaire [23–25]), and other self-reported behaviors. VACS
also extracts VA electronic medical record data, including body
mass index (BMI), diagnoses (recorded using International Classiﬁcation of Diseases, Ninth Revision [ICD-9] diagnostic codes),
procedures, laboratory results, and VA-dispensed medications
[26]. Approval was obtained by the institutional review boards
at each participating VA medical center.
Study Participants

Patients enrolled in the VACS between 1 June 2002 and 30 September 2010 and reporting alcohol consumption on the
AUDIT-C at enrollment were eligible for inclusion. Participants
were excluded if they (1) denied alcohol use in the prior 12
months or (2) did not have laboratory results available to determine FIB-4 index at enrollment. We excluded patients who did
not consume alcohol to avoid inclusion of sick abstainers (ie,
persons who avoid drinking alcohol because of former alcohol
abuse, knowledge of the presence of advanced hepatic ﬁbrosis,
or concerns regarding alcohol’s interactions with prescribed
medications), which could bias results [27].
Main Study Outcomes

The primary outcome was advanced hepatic ﬁbrosis, determined
by FIB-4 index. FIB-4 is calculated using aspartate aminotransferase
(AST), alanine aminotransferase (ALT), platelet count, and age as
follows: (age [years] × AST [U/L])/(( platelet count [109/L]) ×
(ALT [U/L])1/2) [18]. A FIB-4 index >3.25 has been shown to
identify advanced hepatic ﬁbrosis (Metavir stage F3 or F4) with a
high degree of accuracy in patients with alcoholic liver disease (area
under the receiver-operating characteristic curve [AUROC], 0.70–
0.80) [13], viral hepatitis (AUROC, 0.85–0.91) [14–17], and HIV/
viral hepatitis coinfection (AUROC, 0.77) [18]. FIB-4 was calculated using age at VACS enrollment and AST, ALT, and platelet
count results measured closest to, but between 12 months before
and 6 months after, enrollment. We used the established cutoff of
FIB-4 index >3.25 to deﬁne advanced hepatic ﬁbrosis [14–16, 18].
To further examine the relationship between alcohol use categories and liver disease, we evaluated 3 secondary outcomes: (1)
signiﬁcant liver ﬁbrosis determined by AST-to-platelet ratio index
(APRI) >1.5, (2) hepatic inﬂammation, and (3) hepatic decompensation. APRI is calculated using AST and platelet count: ([AST
[U/L]/upper limit of normal [considered as 40 U/L])/platelet
count (109/L)] × 100 [28]. An APRI >1.5 accurately identiﬁes signiﬁcant liver ﬁbrosis (Metavir stage F2–F4) in chronic liver

diseases [13, 14, 17, 28–32]. Hepatic inﬂammation was deﬁned by
serum levels of either AST or ALT >40 U/L, as this cutoff reﬂects
a clinically meaningful level of hepatocellular injury [33, 34]. Hepatic decompensation was deﬁned by medical record–conﬁrmed
diagnoses of ascites, spontaneous bacterial peritonitis, esophageal
variceal hemorrhage, or hepatic encephalopathy [35, 36].
Alcohol Use Categories

Alcohol use at enrollment was categorized using responses to
AUDIT-C questions and diagnoses of alcohol-related conditions [37, 38]. AUDIT-C is a 3-item screening test evaluating alcohol consumption within the prior year (ie, frequency of
alcohol use, quantity of alcohol consumed, and consumption
of ≥6 drinks on 1 occasion [binge drinking]) [23]. This instrument has good operating characteristics for the detection of
nonhazardous, hazardous, and binge drinking, but not for the
diagnosis of alcohol abuse or dependence [23–25]. Diagnoses of
alcohol-related conditions (deﬁned by ICD-9 codes 291.x, 303.
x, and 305.0) have been shown to accurately identify active
alcohol dependence/abuse [39]. Because neither AUDIT-C
nor alcohol-related diagnoses can individually capture all levels
of alcohol consumption, we used both measures to categorize
alcohol use. The need, feasibility, and validity of using both psychometric and diagnostic measures of alcohol consumption
have previously been established [40–43], and this methodology
minimizes exposure misclassiﬁcation. Participants reporting alcohol use on the AUDIT-C within the 12 months prior to enrollment were assigned, in a hierarchical manner, to 3 mutually
exclusive alcohol consumption categories: (1) alcohol-related
diagnosis, deﬁned by an ICD-9 diagnosis for alcohol dependence/abuse recorded between 12 months before and 6 months
after VACS enrollment; (2) hazardous or binge drinking in
those without an alcohol-related diagnosis, deﬁned as an
AUDIT-C score ≥4 or report of consumption of ≥6 drinks
on any 1 occasion in the past year; and (3) nonhazardous drinking,
deﬁned as an AUDIT-C score <4 [37–39].
Demographic and Clinical Data

Demographic data collected at VACS enrollment included age,
sex, and race/ethnicity. Clinical data collected between 12 months
before and 6 months after enrollment included BMI, chronic
HCV infection (detectable HCV RNA); active hepatitis B virus
(HBV) infection (positive HBV surface antigen and/or detectable
HBV DNA); history of other chronic liver diseases (ICD-9 diagnosis of nonalcoholic fatty liver disease, autoimmune hepatitis,
primary biliary cirrhosis, α-1 antitrypsin deﬁciency, or Wilson
disease); diabetes mellitus (random glucose ≥200 mg/dL, diabetes
ICD-9 diagnosis, or antidiabetic medication use [44, 45]); HIV-related data (CD4 count; HIV RNA level; use of antiretroviral therapy [ART], deﬁned as at least 3 antiretrovirals from 2 different
classes [46]; and ART regimen); ALT; AST; and platelet count.

Laboratory results measured closest to but between 12 months before and 6 months after enrollment were used in analyses. We
evaluated for the presence of hepatic decompensation at VACS
enrollment as previously described [47].
Statistical Analysis

Differences in characteristics by HIV and chronic HCV status
were assessed using χ2 tests for categorical data and t tests or
Wilcoxon rank-sum tests, as appropriate, for continuous data.
We determined differences in the prevalence of outcomes for
each category of alcohol use, by HIV and chronic HCV status.
Next, we used logistic regression to determine the adjusted odds
ratio (OR) and 95% conﬁdence interval (CI) of advanced hepatic ﬁbrosis associated with alcohol use categories, stratiﬁed by
HIV status. Models were adjusted for sex, race, BMI, diabetes,
HBV infection, chronic HCV, and CD4 count and HIV RNA
level (HIV-infected stratum). We did not control for age because age is a component of the FIB-4 index.
We then evaluated the prevalence of advanced ﬁbrosis for each
alcohol use category among HIV/HCV-coinfected, HIVmonoinfected, HCV-monoinfected, and HIV/HCV-uninfected
participants. We determined adjusted ORs of advanced hepatic ﬁbrosis associated with the alcohol use categories in these 4 groups.
Associations were assessed with a 12-level HIV/HCV and alcohol
use category variable (4 HIV/HCV groups × 3 alcohol levels).
HIV/HCV-uninfected nonhazardous drinkers served as the reference group for all comparisons. Analyses were performed using
SAS software, version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
Participant Characteristics

Among the 7270 participants enrolled in VACS through September 2010, 4611 (63%; 2311 HIV-infected vs 2300 HIVuninfected; P = .7) reported alcohol consumption within the
12 months prior to enrollment, and 5784 (80%; 3312 HIVinfected vs 2472 HIV-uninfected; P < .001) had laboratory
data available to calculate FIB-4. The ﬁnal study sample included
3565 current drinkers with available FIB-4 data (701 HIV/HCVcoinfected; 1410 HIV-monoinfected; 296 HCV-monoinfected;
1158 HIV/HCV-uninfected), of whom 1479 (41.5%) met criteria
for nonhazardous drinking, 1232 (34.6%) for hazardous/binge
drinking, and 854 (24.0%) for an alcohol-related diagnosis
(Table 1). Compared with those excluded due to lack of FIB-4
data, patients included in the study sample were older; more
commonly black, Hispanic, and infected with HIV or viral hepatitis; and less frequently obese (BMI > 30 kg/m2). The groups
were similar for all other characteristics listed in Table 1.
Compared to HIV-uninfected persons, those with HIV were
younger (median, 48 vs 50 years), more commonly black (66.2%
vs 62.4%), and more frequently infected with HBV (4.3% vs
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Table 1. Characteristics of Participants Reporting Alcohol Use at Enrollment in the Veterans Aging Cohort Study, Overall and by
HIV/Chronic Hepatitis C Virus Status
Overall
(N = 3565)

Characteristic

HIV/HCV-Coinfected
(n = 701)

Age, median (IQR)
Age ≥50 y

49 (43–55)
1706 (47.9)

50 (47–54)
382 (54.5)

Male sex

3439 (96.5)

687 (98.0)

Race/ethnicity
White

HIV-Monoinfected
(n = 1410)

HCV-Monoinfected
(n = 296)

HIV/HCV-Uninfected
(n = 1158)

47 (41–54)
553 (39.2)

51 (47–54)
159 (53.7)

50 (44–56)
612 (52.8)

1372 (97.3)

285 (96.3)

1095 (94.6)

764 (21.4)

81 (11.6)

364 (25.8)

31 (10.5)

288 (24.9)

2305 (64.7)

529 (75.5)

869 (61.6)

222 (75.0)

685 (59.2)

364 (10.2)
132 (3.7)

62 (8.8)
29 (4.1)

127 (9.0)
50 (3.5)

36 (12.2)
7 (2.4)

139 (12.0)
46 (4.0)

1479 (41.5)
1232 (34.6)

242 (34.5)
249 (35.5)

719 (51.0)
512 (36.3)

60 (20.3)
70 (23.6)

458 (39.6)
401 (34.6)

Alcohol-related diagnosis

854 (24.0)

210 (30.0)

179 (12.7)

166 (56.1)

299 (25.8)

Hepatitis B virus infectiona
Hepatitis C virus infectionb

117 (3.3)
997 (28.0)

37 (5.3)
701 (100.0)

54 (3.8)
0 (0.0)

13 (4.4)
296 (100.0)

13 (1.1)
0 (0.0)

Black
Hispanic
Other
Alcohol category
Nonhazardous
Hazardous or binge

Hepatitis C RNA
<400 000 IU/mL and/or
<1 000 000 copies/mL

55 (7.8)

20 (6.8)

≥400 000 IU/mL and/or
≥1 000 000 copies/mL
Qualitative HCV RNA
result only

204 (29.1)

56 (18.9)

442 (63.1)

220 (74.3)

Other chronic liver disease
Diabetes mellitus

32 (0.9)
469 (13.2)

12 (1.7)
86 (12.3)

6 (0.4)
138 (9.8)

9 (3.0)
49 (16.6)

5 (0.4)
196 (16.9)

26 (23–30)
844 (23.7)

24 (22–27)
87 (12.4)

25 (22–28)
210 (14.9)

26 (23–30)
73 (24.7)

29 (26–33)
474 (40.9)

HIV RNA, log copies/mL,
median (IQR)

2.8 (1.9–4.3)

2.9 (1.9–4.2)

HIV RNA ≤400 copies/mL
CD4 cell count, cells/µL,
median (IQR)

336 (47.9)
345 (194–515)

624 (44.3)
375 (228–564)

Body mass index
Median (IQR)
≥30 kg/m2

CD4 cell count
<200 cells/µL
200–500 cells/µL
>500 cells/µL
On antiretroviral therapy

181 (25.8)

302 (21.4)

333 (47.5)

656 (46.5)

187 (26.7)
578 (82.5)

452 (32.1)
1165 (82.6)

Protease inhibitor

330 (47.1)

608 (43.1)

Nonnucleoside reverse
transcriptase inhibitor

221 (31.5)

525 (37.2)

Nucleos(t)ide reverse
transcriptase inhibitor

569 (81.2)

1157 (82.1)

Data are presented as No. (%) unless otherwise specified.
Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; IU, international units.
a

Defined by positive hepatitis B surface antigen and/or detectable hepatitis B virus DNA.

b

Defined by detectable hepatitis C virus RNA.

1.8%) or chronic HCV (30.6% vs 18.9%), but less commonly
had diabetes mellitus (10.6% vs 16.9%) or obesity (14.1% vs
37.6%). Twenty-three percent of HIV-infected patients had a
CD4 count <200 cells/µL, and 83% received ART. As alcohol
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use category increased, the mean CD4 count decreased (nonhazardous: 417 cells/µL; hazardous/binge: 402 cells/µL;
alcohol-related diagnosis: 384 cells/µL; test for trend, P = .04)
and mean HIV RNA level increased (nonhazardous: 3.1 log

copies/mL; hazardous/binge: 3.2 log copies/mL; alcohol-related
diagnosis: 3.3 copies/L; test for trend, P = .01).
Advanced Hepatic Fibrosis, by HIV and Chronic HCV Status

Overall, 271 (7.6%) participants had advanced hepatic ﬁbrosis
(FIB-4 >3.25). Advanced ﬁbrosis was more prevalent among
HIV-infected than -uninfected (210 [9.9%] vs 61 [4.2%];
P < .001) and chronic HCV-infected than -uninfected (182
[18.3%] vs 89 [3.5%]; P < .001) patients. Among HIV-infected
and -uninfected (Table 2) and chronic HCV-infected and -uninfected (Table 2) participants, the prevalence of advanced hepatic
ﬁbrosis increased as the category of alcohol use increased, with the
lowest prevalence among nonhazardous drinkers, an increased
prevalence among participants who reported hazardous/binge
drinking, and the highest prevalence among those with an
alcohol-related diagnosis. For each category of alcohol use, HIVinfected (Table 2) or chronic HCV-infected (Table 2) patients
more commonly had advanced hepatic ﬁbrosis than uninfected
patients. Similar patterns were observed for signiﬁcant liver ﬁbrosis, hepatic inﬂammation, and hepatic decompensation (Table 2).

In multivariable analyses, category of alcohol use remained
independently associated with advanced hepatic ﬁbrosis in
HIV-infected (P = .001) and -uninfected (P = .003) persons
(Table 3). Results were similar when the outcome was signiﬁcant liver ﬁbrosis (APRI >1.5; Supplementary Appendix 1).
The prevalence of advanced hepatic ﬁbrosis increased with
higher alcohol use category among HIV/HCV-coinfected,
HIV-monoinfected, HCV-monoinfected, and HIV/HCV-uninfected patients (Figure 1). For each alcohol use category, the
prevalence of advanced hepatic ﬁbrosis was highest among
HIV/HCV-coinfected participants. In multivariable analysis,
the ORs of advanced hepatic ﬁbrosis increased with greater severity of alcohol use categories within each of the 4 groups (Figure 2; Supplementary Appendix 2). The strongest associations
with advanced hepatic ﬁbrosis were observed among HIV/
HCV-coinfected patients with nonhazardous drinking (OR,
14.2; 95% CI, 5.91–34.0), hazardous/binge drinking (OR, 18.9;
95% CI, 7.98–44.8), and alcohol-related diagnoses (OR, 25.2;
95% CI, 10.6–59.7) compared with uninfected nonhazardous
drinkers.

Table 2. Prevalence of Hepatic Outcomes of Interest for Speciﬁed Alcohol Use Categories, by HIV and Chronic Hepatitis C Virus Infection
Status, Among Patients Reporting Current Alcohol Use at Enrollment in the Veterans Aging Cohort Study (N = 3565)
Markers of Advanced
Hepatic Fibrosisa,b

Markers of Significant
Liver Fibrosisa,b

Markers of Hepatic
Inflammationa,b

(FIB-4 >3.25)

(APRI >1.5)

(ALT or AST >40 U/L)

No. at Risk
Outcome

−

HIV

−

HIV

HIV

HIV

HIV

HIV−

HIV+

HIV−

HIV+

61 (4.2)

210 (9.9)

51 (3.5)

168 (8.0)

480 (33.0)

908 (43.0)

11 (0.8)

34 (1.6)
11 (1.1)

+

HIV

+

−

Hepatic
Decompensationb,c

+

Prevalence of hepatic outcomes by HIV status
Overall

1454

2111

Alcohol use category
Nonhazardous

518

961

7 (1.4)

64 (6.7)

0 (0.0)

47 (4.9)

141 (27.2)

354 (36.8)

0 (0.0)

Hazardous or binge

471

761

14 (3.0)

72 (9.5)

11 (2.3)

57 (7.5)

156 (33.1)

318 (41.8)

2 (0.4)

8 (1.1)

Alcohol-related
diagnosis

465

389

40 (8.6)

74 (19.0)

40 (8.6)

64 (16.5)

183 (39.4)

236 (60.7)

9 (1.9)

15 (3.9)

<.001

<.001

HCV−

+

χ2 test for trend P value

<.001
HCV

<.001

HCV−

<.001

<.001

<.001

.002

HCV+

HCV−

HCV+

HCV−

HCV

HCV−

HCV+

+

Prevalence of hepatic outcomes by chronic HCV status
Overall

2568

997

89 (3.5)

182 (18.3)

55 (2.1)

164 (16.4)

686 (26.7)

702 (70.4)

18 (0.7)

27 (2.7)

Alcohol use category
Nonhazardous

1177

302

30 (2.5)

41 (13.6)

14 (1.2)

33 (10.9)

293 (24.9)

202 (66.9)

7 (0.6)

4 (1.3)

Hazardous or binge

913

319

28 (3.1)

58 (18.2)

18 (2.0)

50 (15.7)

248 (27.2)

226 (70.8)

3 (0.3)

7 (2.2)

Alcohol-related
diagnosis

478

376

31 (6.5)

83 (22.1)

23 (4.8)

81 (21.5)

145 (30.3)

274 (72.9)

8 (1.7)

16 (4.3)

.022

.093

χ2 for trend P value

<.001

.005

<.001

<.001

.065

.018

Data are presented as No. (%) unless otherwise specified.
Abbreviations: ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human
immunodeficiency virus.
a

χ2 test for effect of HIV infection within alcohol category; P < .01.

b

χ2 test for effect of chronic HCV infection within alcohol category; P < .01.

c

χ2 test for effect of HIV infection within alcohol category; P = .025.
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Table 3. Evaluation of the Association Between Alcohol Use Categories and Advanced Hepatic Fibrosis (Deﬁned by FIB-4 Index >3.25),
Controlling for Speciﬁed Variables, Among HIV-Infected and -Uninfected Patients Reporting Current Alcohol Use at Enrollment in the
Veterans Aging Cohort Study (N = 3565)
HIV-Infected (n = 2111)
FIB-4 >3.25
Characteristic

HIV-Uninfected (n = 1454)
a

Adjusted Odds Ratio
(95% CI)

FIB-4 >3.25
No.

Adjusted Odds Ratiob

No.

(%)

(%)

(95% CI)

Nonhazardous

64

(6.7)

Ref.

7

(1.4)

Ref.

Hazardous or binge
Alcohol-related diagnosis

72
74

(9.5)
(19.0)

1.26
2.05

(.87–1.82)
(1.39–3.02)

14
40

(3.0)
(8.6)

1.98
4.00

(.78–5.04)
(1.70–9.41)

207
3

(10.1)
(5.8)

Ref.
0.58

(.17–2.01)

59
2

(4.3)
(2.7)

Ref.
.86

(.19–3.93)

31
148

(7.0)
(10.6)

Ref.
0.88

(.57–1.36)

8
39

(2.5)
(4.3)

Ref.
1.08

(.48–2.84)

25
6

(13.2)
(7.6)

1.47
0.72

(.81–2.67)
(.27–1.88)

11
3

(6.3)
(5.7)

2.07
2.07

(.78–5.52)
(.48–9.04)

182
28

(9.6)
(12.5)

Ref.
1.39

(.88–2.20)

52
9

(4.3)
(3.7)

Ref.
0.96

(.45–2.05)

187
23

(10.3)
(7.7)

Ref.
0.89

(.55–1.45)

48
13

(5.3)
(2.4)

Ref.
0.69

(.36–1.33)

193
17

(9.6)
(18.7)

Ref.
1.72

(.94–3.14)

54
7

(3.8)
(26.9)

Ref.
4.13

(1.53–11.16)

80
146

(5.5)
(20.8)

Ref.
5.03

(3.62–6.97)

26
36

(2.2)
(12.2)

Ref.
4.37

(2.50–7.64)

121
89

(7.4)
(18.4)

Ref.
2.46

(1.78–3.40)

77
133

(8.0)
(11.5)

Ref.
1.37

(.99–1.89)

Alcohol use category

Sex
Men
Women
Race/ethnicity
White
Black
Hispanic
Other
Diabetes
No
Yes
Body mass index, kg/m2
<30
≥30
HBV infectionc
No
Yes
Chronic HCV infectiond
No
Yes
CD4 cell count, cells/µL
≥200
<200
HIV RNA, copies/mL
<400
≥400

Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
a
Adjusted odds ratios for HIV-infected patients were determined using a multivariable logistic regression model that included terms for alcohol use category, sex,
race/ethnicity, diabetes mellitus, body mass index, HBV infection status, chronic HCV infection status, CD4 cell count, and HIV RNA level at the time of enrollment in
the Veterans Aging Cohort Study.
b
Adjusted odds ratios for HIV-uninfected patients were determined using a multivariable logistic regression model that included terms for alcohol use category, sex,
race/ethnicity, diabetes mellitus, body mass index, HBV infection status, and chronic HCV infection status at the time of enrollment in the Veterans Aging Cohort
Study.
c

Defined by positive hepatitis B surface antigen and/or detectable HBV DNA.

d

Defined by detectable HCV RNA.

DISCUSSION
Our study found that advanced hepatic ﬁbrosis by FIB-4 was
present at low levels of alcohol consumption across groups stratiﬁed by HIV/HCV status. For each alcohol use category,
advanced hepatic ﬁbrosis was more common among HIV-
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infected than -uninfected and chronic HCV-infected than -uninfected patients. In addition, increasing categories of alcohol
use were associated with a higher prevalence of advanced hepatic ﬁbrosis among HIV/HCV-coinfected, HCV-monoinfected,
HIV-monoinfected, and HIV/HCV-uninfected persons. Alcohol use category remained independently associated with

Figure 1. Prevalence of advanced hepatic ﬁbrosis (deﬁned by FIB-4 index
>3.25) according to category of alcohol use (ie, nonhazardous drinking, hazardous or binge drinking, alcohol-related diagnosis), by human immunodeﬁciency virus (HIV) and chronic hepatitis C virus (HCV) infection status, in
patients reporting current alcohol use at enrollment in the Veterans Aging
Cohort Study (N = 3565). *χ2 test for trend over categories of alcohol use
for HIV/HCV-uninfected, P = .019. ^χ2 test for trend over categories of alcohol use for HCV-monoinfected, P < .001. †χ2test for trend over categories
of alcohol use for HIV-monoinfected, P = .0025. ‡χ2 test for trend over categories of alcohol use for HIV/HCV-coinfected, P = .060.

advanced hepatic ﬁbrosis in both HIV-infected and -uninfected
persons. Finally, when we evaluated associations between alcohol use categories and advanced hepatic ﬁbrosis across groups
stratiﬁed by HIV/HCV status, the strongest associations were
observed among those with HIV/HCV coinfection. These results provide new data that suggest that there is a stepwise increased risk of advanced liver ﬁbrosis with greater severity of
alcohol use. They also demonstrate that all alcohol use categories are strongly associated with advanced hepatic ﬁbrosis in
HIV/HCV-coinfected patients.
The reasons for the higher prevalence of advanced hepatic
ﬁbrosis at each category of alcohol use among HIV-infected
or chronic HCV-infected patients compared to uninfected
persons remain unclear. In vitro data have demonstrated that
HIV and HCV can each induce hepatocyte apoptosis [48],
and the addition of alcohol may accelerate this process. Moreover, the hepatic inﬂammation and ﬁbrosis induced by alcohol
may be additive in the setting of HIV-associated immune dysfunction/dysregulation and HCV-related liver inﬂammation [49–51]. Alternatively, the hepatotoxicity of antiretroviral
and nonantiretroviral drugs may be exacerbated by alcohol
consumption in the setting of HIV or chronic HCV infection [52]. Future studies should evaluate the mechanisms by

Figure 2. Odds ratio of advanced hepatic ﬁbrosis (deﬁned by FIB-4 index
>3.25) for category of alcohol use (ie, nonhazardous drinking, hazardous or
binge drinking, alcohol-related diagnosis), by human immunodeﬁciency
virus (HIV) and hepatitis C virus (HCV) infection status, in patients reporting
current alcohol use at enrollment in the Veterans Aging Cohort Study
(N = 3565). Model adjusted for hepatitis B virus infection. Reference category is HIV/HCV-uninfected nonhazardous drinkers.

which alcohol contributes to liver disease progression in HIVmonoinfected, HCV-monoinfected, and HIV/HCV-coinfected
patients.
Our results have several clinical implications. First, the 3-item
AUDIT-C questionnaire could be administered by HIV practitioners during routine practice to ascertain and categorize patients’ alcohol consumption [38]. Knowledge of the alcohol
use category and its potential effects on various organ systems,
such as the liver, might motivate patients to reduce or discontinue alcohol consumption. Second, given the strong associations between all alcohol use categories and advanced hepatic
ﬁbrosis among HIV/HCV-coinfected patients, clinicians should
particularly counsel these patients to decrease their alcohol use,
even with low levels of consumption. Finally, any patient with a
FIB-4 >3.25 should be counseled to reduce or avoid alcohol
consumption.
Our results extend the observations of 2 prior studies examining the relationship between alcohol consumption and advanced liver ﬁbrosis in HIV-infected patients. Chaudhry et al
[6] conducted a cross-sectional study within the Johns Hopkins
HIV Clinical Cohort and observed that hazardous drinking was
associated with an APRI >1.5 in HIV-monoinfected, but not
HIV/HCV-coinfected, patients. Fuster et al [53] performed a
cross-sectional analysis among HIV-infected patients with current or past alcohol problems enrolled in the HIV-Longitudinal
Interrelationships of Viruses and Ethanol (HIV-LIVE) study.
No association was observed between lifetime alcohol use and
either FIB-4 >3.25 or APRI >1.5, regardless of HCV status. Differences in the way that alcohol use was categorized and the
smaller samples of patients who reported alcohol consumption
in those studies might account for the disparate results. Neither
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study included HIV-uninfected patients, as was done in the present analysis.
Our study has several potential limitations. First, because
cross-sectional studies evaluate exposure and disease status simultaneously, our analysis is limited in its ability to determine
whether alcohol use category preceded or resulted from advanced hepatic ﬁbrosis. Being informed about the presence of
hepatic ﬁbrosis, either through invasive or noninvasive modalities, may prompt patients to decrease or cease alcohol consumption. Because of this phenomenon of sick abstainers, we
chose to exclude participants who did not report current alcohol use. Among current drinkers, reverse causality seems less
likely. The cross-sectional design also did not permit us to evaluate changes in hepatic outcomes over time.
Second, we cannot exclude the possibility that some individuals were misclassiﬁed by FIB-4 due to conditions that can decrease the platelet count or that transiently increase liver
aminotransferase levels. However, FIB-4 has been validated to
identify advanced hepatic ﬁbrosis among individuals with alcoholic liver disease [13], viral hepatitis [14–17], and HIV/viral
hepatitis coinfection [18]. Further, we conducted parallel analyses evaluating APRI, liver inﬂammation, and hepatic decompensation and observed consistent results and relationships.
Hepatic ﬁbrosis would ideally be assessed with liver biopsy,
but the acceptability, cost, and risk of liver biopsy in large cohorts of patients make such a study impractical. Further, liver
biopsy itself is an imperfect measure as it is subject to sampling
error and interobserver variability in histological assessment
[54, 55]. Future studies could use other noninvasive modalities,
such as transient elastography, to assess the degree of hepatic
ﬁbrosis [56].
Third, as with any observational study, there is the possibility
of residual confounding. We were unable to account for lifetime
history of alcohol consumption [57], but such measures are currently unable to classify patterns of alcohol use [58]. We also did
not have durations of HIV or HCV infections and did not collect all potential hepatotoxic medications.
Finally, our study sample was predominantly comprised of
male US veterans of black race, potentially limiting the generalizability of our results. Because liver ﬁbrosis progression may
differ by sex and race [59–61], future epidemiologic analyses
should evaluate the relations between alcohol use categories
and hepatic outcomes among women and persons of other
races.
In summary, our ﬁndings suggest that increased category of
alcohol use is associated with a correspondingly higher risk of
advanced hepatic ﬁbrosis. In addition, for each category of alcohol use, advanced hepatic ﬁbrosis was more common among
persons infected with HIV or chronic HCV than among uninfected individuals. Strong associations between all categories of
alcohol use and advanced hepatic ﬁbrosis were observed among
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HIV/HCV-coinfected patients. Future longitudinal studies
should evaluate the mechanisms for the increased liver injury
associated with alcohol consumption in the setting of HIV
and chronic HCV infection and characterize the impact of nonhazardous alcohol consumption and binge drinking on liver ﬁbrosis progression over time to help determine whether there is
a safe level of alcohol exposure.
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